Ligand-lytic peptides for specific targeting of Leishmania major and Trypanosoma cruzi parasites
Frontiers in Cellular and Infection Microbiology · 2025
DOI: 10.3389/fcimb.2025.1595333 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2025. Verfasst von Eva Iniguez und 4 weiteren Autor:innen. Beteiligte Einrichtung: Border Biomedical Research Center, Bioscience Research Building, Department of Biological Sciences, The University of Texas at El Paso, El Paso, TX, …. Hauptthemen laut MEDLINE: Trypanosoma cruzi, Leishmania major, Peptides, Antiprotozoal Agents. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCRR NIH HHS, NIMHD NIH HHS, NIGMS NIH HHS.
Abstract (Originalsprache)
Introduction
Leishmaniasis and Chagas disease are major human neglected diseases, affecting an estimate of 12 and 6 to 8 million people worldwide, respectively. Current treatments for both diseases are highly toxic for the vertebrate host and lack specificity for the parasites, highlighting the need for the discovery of new therapies against these diseases. In this study, we tested the use of the lytic peptide Hecate and a Ligand-Hecate construct that incorporates a ligand to bind the lytic peptide to protozoa membranes and screened them for protozoacidal activity.
Methods
We first screened parasite survival of luciferase expressing Leishmania major promastigotes and Trypanosoma cruzi epimastigotes in the presence of Hecate or Ligand-Hecate , and after 12, 48 and 96 h by measuring the parasite luciferase activity. In addition, High-Content Imaging Assay was used to evaluate the proliferation of intracellular L. major amastigotes propagated inside murine macrophages after treatment with Hecate or Ligand-Hecate .
Results
The lowest half maximal effective concentration observed after 48 h of incubation with Hecate and Ligand-Hecate was lower against L. major promastigotes than T. cruzi epimastigotes. Ligand-Hecate treatment significantly reduced infection rate of macrophages L. major amastigotes compared to the non-treated vehicle control; while treatment with Hecate was significant only at higher drug concentrations. Importantly, no significant cytotoxicity was observed when screened against intraperitoneal murine macrophages for either Hecate or Ligand-Hecate treatments.
Discussion
Our results indicate that ligand-lytic peptide complexes are potential targets for therapeutic drugs that can selectively kill both extracellular and intracellular protozoa parasites stages with no significant toxicity to host cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Border Biomedical Research Center, Bioscience Research Building, Department of Biological Sciences, The University of Texas at El Paso, El Paso, TX, United States.
- Department of Entomology, Louisiana State University Agricultural Center, Baton Rouge, LA, United States.
Förderung
- NCRR NIH HHS
- NIMHD NIH HHS
- NIGMS NIH HHS
Zitieren
APA
Iniguez, E., Rodriguez, F., Husseneder, C., Foil, L., & Maldonado, R. A. (2025). Ligand-lytic peptides for specific targeting of Leishmania major and Trypanosoma cruzi parasites. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2025.1595333
Vancouver
Iniguez E, Rodriguez F, Husseneder C, Foil L, Maldonado RA. Ligand-lytic peptides for specific targeting of Leishmania major and Trypanosoma cruzi parasites. Frontiers in Cellular and Infection Microbiology. 2025. doi:10.3389/fcimb.2025.1595333
BibTeX
@article{Iniguez2025,
author = {Iniguez, Eva and Rodriguez, Felipe and Husseneder, Claudia and Foil, Lane and Maldonado, Rosa A},
title = {Ligand-lytic peptides for specific targeting of Leishmania major and Trypanosoma cruzi parasites},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2025},
doi = {10.3389/fcimb.2025.1595333}
}
EUVIMED